Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies
Background The emergence of SARS-CoV-2 becomes life-threatening for the older and immunocompromised individuals, whereas limited treatment is available on these populations. Mesenchymal stromal cells (MSCs) have been reported to be useful in SARS-CoV-2 treatment and reduce SARS-CoV-2-related sequelae. Results In this study, we developed an autonomous cellular machine to secret neutralizing antibody in vivo constantly based on the clinical-grade MSCs, to combat SARS-CoV-2 infections. First, various modified recombinant plasmids were constructed and transfected into clinical-grade MSCs by electroporation, for assembly and expression of neutralizing anti-SARS-CoV-2 antibodies. Second, the stable antibody secreting MSCs clones were screened through pseudovirus neutralization assay. Finally, we investigated the pharmacokinetics and biodistribution of neutralizing antibody secreted by engineered MSCs in vivo. The stable clinical-grade MSCs clones, expressing XGv347-10 and LY-CoV1404-5 neutralizing antibodies, exhibited their feasibility and protective efficacy against SARS-CoV-2 infection. Transplanted engineered clinical-grade MSCs effectively delivered the SARS-CoV-2 antibodies to the lung, and the immune hyperresponsiveness caused by COVID-19 was coordinated by MSC clones through inhibiting the differentiation of CD4 + T cells into Th1 and Th17 subpopulations. Conclusions Our data suggested that engineered clinical-grade MSCs secreting effective neutralizing antibodies as cellular production machines had the potential to combat SARS-CoV-2 infection, which provided a new avenue for effectively treating the older and immunocompromised COVID-19 patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cell & bioscience - 13(2023), 1 vom: 31. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yanning [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Anti-SARS-CoV-2 antibodies |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s13578-023-01099-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052947718 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052947718 | ||
| 003 | DE-627 | ||
| 005 | 20231120064807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230901s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13578-023-01099-z |2 doi | |
| 035 | |a (DE-627)SPR052947718 | ||
| 035 | |a (SPR)s13578-023-01099-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Yanning |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background The emergence of SARS-CoV-2 becomes life-threatening for the older and immunocompromised individuals, whereas limited treatment is available on these populations. Mesenchymal stromal cells (MSCs) have been reported to be useful in SARS-CoV-2 treatment and reduce SARS-CoV-2-related sequelae. Results In this study, we developed an autonomous cellular machine to secret neutralizing antibody in vivo constantly based on the clinical-grade MSCs, to combat SARS-CoV-2 infections. First, various modified recombinant plasmids were constructed and transfected into clinical-grade MSCs by electroporation, for assembly and expression of neutralizing anti-SARS-CoV-2 antibodies. Second, the stable antibody secreting MSCs clones were screened through pseudovirus neutralization assay. Finally, we investigated the pharmacokinetics and biodistribution of neutralizing antibody secreted by engineered MSCs in vivo. The stable clinical-grade MSCs clones, expressing XGv347-10 and LY-CoV1404-5 neutralizing antibodies, exhibited their feasibility and protective efficacy against SARS-CoV-2 infection. Transplanted engineered clinical-grade MSCs effectively delivered the SARS-CoV-2 antibodies to the lung, and the immune hyperresponsiveness caused by COVID-19 was coordinated by MSC clones through inhibiting the differentiation of CD4 + T cells into Th1 and Th17 subpopulations. Conclusions Our data suggested that engineered clinical-grade MSCs secreting effective neutralizing antibodies as cellular production machines had the potential to combat SARS-CoV-2 infection, which provided a new avenue for effectively treating the older and immunocompromised COVID-19 patients. | ||
| 650 | 4 | |a MSC |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anti-SARS-CoV-2 antibodies |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Gene modification |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a mAbs delivery platform |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Gao, Tianyun |4 aut | |
| 700 | 1 | |a Li, WanTing |4 aut | |
| 700 | 1 | |a Tai, Chenxu |4 aut | |
| 700 | 1 | |a Xie, Yuanyuan |4 aut | |
| 700 | 1 | |a Chen, Dong |4 aut | |
| 700 | 1 | |a Liu, Shuo |4 aut | |
| 700 | 1 | |a Huang, Feifei |4 aut | |
| 700 | 1 | |a Wang, Wenqing |4 aut | |
| 700 | 1 | |a Chen, Yuxin |4 aut | |
| 700 | 1 | |a Wang, Bin |0 (orcid)0000-0003-3981-8849 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell & bioscience |d London : BioMed Central, 2011 |g 13(2023), 1 vom: 31. Aug. |w (DE-627)SPR031850324 |w (DE-600)2593367-X |x 2045-3701 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:31 |g month:08 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13578-023-01099-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 31 |c 08 | ||